TrialThe Lancet. Oncology2016

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Brigitta G Baumert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.